Supernus 製藥公司
US ˙ NasdaqGM ˙ US8684591089

SecuritySUPN / Supernus Pharmaceuticals, Inc.
InstitutionRoyce Value Trust Inc
Latest Disclosed Ownership29,445 shares
Latest Disclosed Value $ 928,106
Royce Value Trust Inc reports 38.45% increase in ownership of SUPN / Supernus Pharmaceuticals, Inc.

On August 15, 2025 - Royce Value Trust Inc filed a NPORT-P form disclosing ownership of 29,445 shares of Supernus Pharmaceuticals, Inc. (US:SUPN) valued at $928,106 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 19, 2025 disclosing 21,268 shares of Supernus Pharmaceuticals, Inc.. This represents a change in shares of 38.45% during the quarter. The current value of the position is $1,317,664 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-15 2025-06-30 NP Supernus Pharmaceuticals EC US8684591089 29,445 8,177 38.45 928 33.33 0.0463
2025-05-19 2025-03-31 NP Supernus Pharmaceuticals EC US8684591089 21,268 11,644 120.99 697 100.00 0.0378
2025-02-21 2024-12-31 NP Supernus Pharmaceuticals EC US8684591089 9,624 -5,898 -38.00 348 -18.50 0.0174
2023-11-22 2023-09-30 NP Supernus Pharmaceuticals EC US8684591089 15,522 5,076 48.59 428 26.71 0.0257
2022-05-16 2022-03-31 NP Supernus Pharmaceuticals EC US8684591089 10,446 -16,160 -60.74 338 -56.52 0.0176
2022-02-24 2021-12-31 NP Supernus Pharmaceuticals EC US8684591089 26,606 -12,971 -32.77 776 -26.54 0.0361
2021-11-22 2021-09-30 NP Supernus Pharmaceuticals EC US8684591089 39,577 7,293 22.59 1,056 6.14 0.0507
2021-08-24 2021-06-30 NP Supernus Pharmaceuticals EC US8684591089 32,284 2,447 8.20 994 27.27 0.0459
2021-05-17 2021-03-31 NP Supernus Pharmaceuticals EC US8684591089 29,837 3,129 11.72 781 16.39 0.0374
2021-02-19 2020-12-31 NP Supernus Pharmaceuticals EC US8684591089 26,708 624 2.39 672 23.57 0.0356
2020-11-24 2020-09-30 NP Supernus Pharmaceuticals EC US8684591089 26,084 0 0.00 544 -12.28 0.0360
2020-08-19 2020-06-30 NP Supernus Pharmaceuticals EC US8684591089 26,084 1,180 4.74 619 38.17 0.0430
2020-05-27 2020-03-31 NP Supernus Pharmaceuticals EC US8684591089 24,904 2,906 13.21 448 -14.01 0.0400
2020-02-19 2019-12-31 NP Supernus Pharmaceuticals EC 868459108 21,998 -1,581 -6.71 522 -19.47 0.0320
2019-11-25 2019-09-30 NP Supernus Pharmaceuticals EC US8684591089 23,579 23,579 648 0.0433
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.